Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

Alex Diamantopoulos,Axel Finckh,Tom W. J. Huizinga,D.K. Sungher,Laura Sawyer,D. Neto,F. Dejonckheere

Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

2014

Alex Diamantopoulos
Axel Finckh
Tom W. J. Huizinga
D.K. Sungher
Laura Sawyer
D. Neto
F. Dejonckheere

Background Since receiving a positive recommendation in England, Wales and Scotland, tocilizumab (TCZ) is one of the options available to clinicians for the treatment of rheumatoid arthritis (RA) patients in the UK.

Keywords:

Physical therapy
Intensive care medicine
Tocilizumab
Rheumatoid arthritis
Cost-effectiveness analysis
Interleukin 6
Methotrexate
Medicine
Quality of life
palliative care
Quality of Life Research
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations